Abstract. Chordomas are locally destructive tumors with high rates of recurrence and a poor prognosis. The mechanisms involved in chordoma recurrence remain largely unknown. In the present study, we examined the proteomic profile of a chordoma primary tumor (CSO) and a recurrent tumor (CSR) through mass spectrum in a chordoma patient who underwent surgery. Bioinformatic analysis of the profile showed that 359 proteins had a significant expression difference and 21 pathways had a striking alteration between the CSO and the CSR. The CSR showed a significant increase in carbohydrate metabolism. Immunohistochemistry (IHC) confirmed that the cancer stem cell marker activated leukocyte cell adhesion molecule (ALCAM or CD166) expression level was higher in the recurrent than that in the primary tumor. The present study analyzed the proteomic profile change between CSO and CSR and identified a new biomarker ALCAM in recurrent chordomas. This finding sheds light on unraveling the pathophysiology of chordoma recurrence and on exploring more effective prognostic biomarkers and targeted therapies against this devastating disease.
Introduction
Chordoma is a rare slow-growing neoplasm thought to arise from cellular remnants of the notochord. The incidence of chordoma is approximately 1 case in one million individuals and it accounts for ~1-4% of all tumor cases. However, these rare tumors present very significant treatment challenges (1) . It is notable that 67% of the surgically managed patients suffer local recurrence, and the disease-free survival at 5 years is almost 0% (1, 2) .
Complete surgical resection followed by radiation therapy offers the best chance of long-term control for chordoma. However, incomplete resection of the primary tumor makes controlling the disease more difficult and increases the odds of recurrence. Tumors at certain sites such as skull base chordoma can hardly be removed completely due to the complicated peritumoral tissue structure which makes the tumor difficult to be exposed. Thus, recurrence of skull base chordoma is as high as 85%. Chordomas are relatively radioresistant as well, requiring high doses of radiation to be controlled. The proximity of chordomas to vital neurological structures such as the brain stem and nerves limits the dose of radiation that can safely be delivered. A strategy to control the recurrence of chordomas is vital for improving the survival rate of patients. It is imperative to explore chordoma recurrence mechanisms at the molecular level and to search for alternative therapeutic methods including chemotherapy to treat it. Recently, Zhou et al assessed the chordoma proteome in chordoma tumor tissues and identified ENO1, PKM2, and gp96 proteins as being upregulated in chordomas. They reported that the expression of these proteins was higher in recurrent than that in the primary chordomas (3) . However, the molecular mechanisms involved in chordoma recurrence remain unstudied, and the detailed changes in proteomic profiling in the process of recurrence remain unclear.
We analyzed 3,296 proteins identified by mass spectrum in a chordoma patient original tumor (CSO) and recurrent tumor (CSR) tissue. Bioconductor's Global Anova test was applied to compare the overall proteomic profiling changes between CSO and CSR which indicated there was a significant difference (P≤0.1). Bioconductor's multtest found that 359 proteins exhibited the highest expression difference between CSO and CSR. KEGG database analysis of the 359 proteins revealed that 21 pathways had a significant change between CSO and CSR. Immunohistochemistry (IHC) further verified that cancer stem cell marker activated leukocyte cell adhesion molecule (ALCAM or CD166) was markedly upregulated in the CSR tissue. Immunohistochemistry. The paraffin sections were dried in an oven at 65˚C for 1 h. The paraffin sections were then dewaxed in xylene and rehydrated in a series of ethanol solutions. The endogenous peroxidase activity was blocked by a 10-min pre-incubation with 3% H 2 O 2 . The paraffin sections were preheated at 100˚C in antigen retrieval solution containing EDTA (pH 8.0) for 30 min and blocked by non-immune goat serum at room temperature for 15 min to decrease unspecific staining. Incubation with mouse polyclonal anti-ALCAM (1:1,000 dilution) was performed overnight at 4˚C. After being washed 3 times with 1X PBS buffer for 3 min, the sections were incubated with the secondary (link) antibody (biotinylated mouse-anti-human IgG) for 30 min at room temperature. After reacting with the streptavidin-biotin-peroxidase complex for 20 min, the immunoreactivity was determined by 3,3'-diamino-benzidine tetrahydrochloride and H 2 O 2 at room temperature according to the manufacturer's instructions. The positive reaction was manifested as brown (DAB) staining. The sections were counterstained in Mayer's hematoxylin. The selected sections were scanned at x400 magnification to visualize the localization and distribution of ALCAM. Moreover, a positive expression ratio represents upregulation and negative represents downregulation. Blast2Go (8) was used as a comprehensive bioinformatics tool for the functional annotation of the protein sequences in the present study such as determining gene ontology terms. The metabolic map at CSR was generated by first using the statistically significant proteins to identify the key pathways. Once the pathways were identified, all of the detected proteins in the same pathway were evaluated to determine whether they were upregulated or downregulated relative to the control. If ≥50% of the proteins in the pathway was regulated similarly in the same direction, then the pathway would be designated as upregulated or downregulated according to the majority. The cellular pathways are displayed using the iPath 2.0 platform (9) .
Differential proteomic profiling of primary and recurrent chordomas

Results and Discussion
In order to obtain a comprehensive proteomic profile of CSO and CSR and to investigate the mechanism of recurrence, the proteome of patient CSO and CSR tumor tissue samples was analyzed with LC/MS. In total, 3,296 unique protein sequences were identified. Bioconductor's Global Anova package was used to determine the significance of the protein expression change between CSO and CSR. A protein expression difference with P≤0.1±0.002 was defined as statistically significant (Table I) . Furthermore, we applied Bioconductor's multtest package to analyze the identified 3,296 proteins and found that a large number of proteins (359) showed significant changes in expression with BH ≤0.01 and P≤0.01 between CSO and CSR. These proteins were involved in central metabolism, genetic information transcription and other processes essential to cell functions. Of these 359 proteins, there were 244 downregulated proteins (CSR/CSO value ≤0.1) and 115 upregulated proteins (CSR/CSO ≥9) ( Fig. 1 ; Table III and IV) . This analysis discovered many significant proteins which have never been reported before in recurrent chordomas. Among the top downregulated proteins, podocan is involved in negative regulation of cell migration and proliferation, concomitant with increased p21 expression which is a tumor-suppressor gene and can mediate cellular senescence (10) . ZO-1 has been shown to be downregulated in poorly differentiated, highly invasive breast cancer cell lines (11) , and downregulation of complement factor I (CFI) is regarded as a potential suppressive protein for gastric cancer identified by serum proteome analysis (12) . Downregulation of osteomodulin (OMD) is referred to in the context of uterine serous papillary carcinoma. It was further disclosed that activation of OMD or/and PRELP gene expression or function can suppress cancer initiation and development (13) . FK506-binding protein 4 (FKBP4) was reported to have cancer-specific methylation which usually inactivates this gene in breast cancer tissues (14) . We are the first to report downregulation of these tumor-suppressing proteins in recurrent chordomas. The markedly decreased expression of these tumor-suppressing proteins suggests that recurrent chordomas are more aggressive than primary chordomas. While the top upregulated proteins included myosin-7 (MYH7) which is related to eukaryotic cell motility; CD166 (ALCAM) has been regarded as a potential cancer stem cell marker (15) . Splicing factor, arginine/serine-rich 2 (SFRS2) demonstrated Wnt signaling-dependent activation which promotes cell migration (16); and Ras-related protein Rab-11A (RAB11A) can differentially modulate epidermal growth factor-induced proliferation and motility in immortal breast cells (17) . These newly identified upregulated molecules in recurrent chordomas by our analysis may be possible biomarkers for diagnosis and/ or targets for treating recurrent chordomas. Our study also provides valuable information for future studies on chordoma recurrence mechanisms which remain unelucidated.
To investigate which signaling pathways have alterations in CSR, we searched the 359 identified proteins with significant change in the KEGG database and found that there were over 21 pathways with Seqs ≥3 between CSO and CSR as shown in Table II . Eight pathways were markedly upregulated in CSR compared with CSO (num upregulated protein ≥60%) and nine pathways were apparently downregulated in CSR compared with CSO (num downregulated protein ≥60%) (Fig. 2) . Notably, most of the upregulated pathways (6 of 8) and cellular components are involved in carbohydrate metabolism indicating that carbohydrate metabolic activity was higher in recurrent chordomas than in primary chordomas (Fig. 2 ). Fig. 3 shows that the top 3 upregulated pathways including butanoate, inositol phosphate and glyoxylate and dicarboxylate metabolism are all involved in carbohydrate metabolism. Those 3 pathways were upregulated by 85.7, 75 and 73.3%, respectively, in the CSR compared with the CSO (Fig. 3) . The glycolysis/gluconeogenesis pathway was also upregulated (Fig. 2) . It has been reported that a high glycolytic rate has advantages for malignant cells (18) . High glycolytic activity produces high levels of lactate and H + ions which are transported outside the cell where they directly promote tumor aggressiveness through invasion and metastasis, two other hallmarks of cancer (19) . Additionally, the genes and pathways that upregulate glycolysis are themselves anti-apoptotic (20) . The increased carbohydrate metabolism in recurrent chordomas suggests that recurrent chordomas have a more aggressive phenotype and are resistant to therapy. The other 2 upregulated pathways in the recurrent chordomas are involved in energy metabolism and amino acid metabolism. In contrast to the upregulated pathways, the downregulated pathways participate in various biological processes and molecular functions including 
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nucleotide metabolism, amino acid metabolism, carbohydrate metabolism, genetic information processing and translation, and biosynthesis of other secondary metabolites.
To further determine the cellular function change between CSO and CRO, the statistically significant 359 proteins identified were classified according to gene ontology Proline-, glutamic acid-and leucine-rich protein 1 GN=PELP1 q8N1G4 Leucine-rich repeat-containing protein 47 GN=LRRC47 q8NE86 Coiled-coil domain-containing protein 109A GN=CCDC109A q8NF37 1-acylglycerophosphocholine O-acyltransferase 1 GN=LPCAT1 q8NFW1 Collagen α-1(XXII) chain GN=COL22A1 q8NI60
Chaperone activity of bc1 complex-like, mitochondrial GN=CABC1 q8WW22 DnaJ homolog subfamily A member 4 GN=DNAJA4 q92629 δ-sarcoglycan GN=SGCD q96A32
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terms. The proteins were found to be involved in either a biological process, a cellular component and/or a molecular function (Fig. 4) , indicating that there were diverse cellular components and catalytic activity change in recurrent chordomas compared to the original chordoma. Furthermore, when the identified proteins in the recurrent chordoma were mapped to the corresponding metabolic pathways, many key cellular pathways including amino acid, carbohydrate metabolism, energy, and nucleotide metabolism were found to be downregulated (Fig. 4) . In order to confirm our results from the proteome, we examined tumor-related protein expression from the list of upregulated proteins through IHC in the chordoma patient primary and CSR tissues. ALCAM (or CD166) is a 100-105 kDa type I transmembrane glycoprotein that is a member of the immunoglobulin superfamily of proteins (21) . ALCAM has been reported as a cancer stem cell marker for non-small cell lung cancer (NSCLC) (15) . Physiologically, it plays a role in the development of different tissues during embryogenesis. It is also expressed in various malignant lesions such as melanoma and esophageal, gynecologic, prostate, and pancreatic cancers, and its expression is associated with diverse outcomes in different tumors (22) (23) (24) (25) (26) (27) (28) (29) (30) (31) (32) . But the expression of ALCAM in chordomas has never been reported and the association between ALCAM and chordoma prognosis is not fully elucidated. In our study, we firstly detected ALCAM expression by using IHC in chordoma patient primary and CSR tissues. Fig. 5A clearly demonstrates that the primary chordoma tumor was negative for staining; however, the CSR had strong expression of ALCAM which suggests that ALCAM is a positive biomarker for recurrent chordomas and may play important roles for chordoma recurrence (Fig. 5B ).
In conclusion, we analyzed the proteomic profile of a chordoma patient CSO and CSR and identified 359 proteins and 21 pathways with significant changes between CSO and CSR. Many of these molecular changes are reported in chordomas for the first time. Further investigation of the potential roles of these proteins in chordoma aggression is of interest. We also firstly found that the recurrent chordoma tumor showed enhanced carbohydrate metabolism, and the cancer stem cell marker ALCAM (CD166) expression level was increased markedly in CSR. The present study can serve as the basis for further research of recurrent chordomas.
